VNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VolitionRX Ltd (VNRX) is not a strong buy for a beginner, long-term investor at this time. Despite a slight pre-market price increase and positive revenue growth in the latest quarter, the stock's technical indicators, lack of significant trading trends, and weak analyst sentiment do not support a compelling entry point. The absence of recent news, congress trading data, and proprietary trading signals further reduces confidence in this stock as a good buy currently.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 54.435, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. Key resistance levels are at 0.187 and 0.197, with support at 0.154 and 0.144.
Revenue increased by 133.25% YoY in Q4 2025, showing strong topline growth. Gross margin remains at 100%.
EPS dropped by 16.67% YoY, and net income remains significantly negative at -$6.27M. Analyst price target was lowered from $1.50 to $1.00, reflecting reduced confidence. No recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, revenue increased by 133.25% YoY to $447,034, while net income improved slightly but remains negative at -$6.27M. EPS dropped to -0.05, down 16.67% YoY. Gross margin stayed at 100%.
H.C. Wainwright maintains a Buy rating but lowered the price target to $1 from $1.50 due to increased share count, despite potential future licensing deals in 2026.
